Asymmetric visible-light photocatalysis has recently drawn considerable attention of the scientific community owing to its unique activation modes and significance for the enantioselective green synthesis.
The design and synthesis of novel planar chiral iodoarenes based on [2.2]paracyclophane is reported. A process of highly enantioselective oxidative fluorination of a β-ketoester with 3HF-EtN as a nucleophilic fluoride source mediated by these new hypervalent iodine catalysts has been developed. This represents the first highly enantioselective reaction catalyzed by planar chiral hypervalent iodine.
The surface and boundary defects present in the perovskite film are reported to be nonradiative recombination and degradation centers, restricting further improvement of the power conversion efficiency (PCE) and long-term stability of perovskite solar cells. To address this problem, herein, we introduce a fluorine-substituted small molecular material 2FBTA-1 as a bifunctional buffer layer to efficiently passivate the surface defects of perovskite and tune the energy level alignment between the perovskite/2,2′,7,7′-tetrakis(N,N-di-(pmethoxyphenyl)amino)-9,9′-spirobifluorene (Spiro-OMeTAD) interface. X-ray photoelectron spectroscopy shows that with the insertion of 2FBTA-1 between perovskite and Spiro-OMeTAD, the metallic Pb 0 defects and uncoordinated Pb 2+ defects are well restricted. Consequently, the average PCE is distinctly improved from 18.4 ± 0.51 to 20.3 ± 0.40%. Moreover, the long-term stability of unencapsulated devices with 2FBTA-1 treatment under ambient conditions (relative humidity 40−60%) is effectively enhanced, retaining 87% of the initial efficiency after storage for 500 h.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.